-
2-{14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl}-2-oxoethyl propanoate
-
ChemBase ID:
1001
-
Molecular Formular:
C27H36O8
-
Molecular Mass:
488.56994
-
Monoisotopic Mass:
488.24101811
-
SMILES and InChIs
SMILES:
O(C1(C2(C(C3C(C(O)C2)C2(C(=CC(=O)C=C2)CC3)C)CC1)C)C(=O)COC(=O)CC)C(=O)OCC
Canonical SMILES:
CCOC(=O)OC1(CCC2C1(C)CC(O)C1C2CCC2=CC(=O)C=CC12C)C(=O)COC(=O)CC
InChI:
InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3
InChIKey:
FNPXMHRZILFCKX-UHFFFAOYSA-N
-
Cite this record
CBID:1001 http://www.chembase.cn/molecule-1001.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
2-{14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl}-2-oxoethyl propanoate
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Dermatop
|
Dermatop E Emollient
|
|
|
Synonyms
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
14.829222
|
H Acceptors
|
6
|
H Donor
|
1
|
LogD (pH = 5.5)
|
3.8318758
|
LogD (pH = 7.4)
|
3.8318756
|
Log P
|
3.8318758
|
Molar Refractivity
|
127.7954 cm3
|
Polarizability
|
50.123066 Å3
|
Polar Surface Area
|
116.2 Å2
|
Rotatable Bonds
|
9
|
Lipinski's Rule of Five
|
true
|
Log P
|
3.08
|
LOG S
|
-4.94
|
Solubility (Water)
|
5.62e-03 g/l
|
PROPERTIES
PROPERTIES
Physical Property
Bioassay(PubChem)
Hydrophobicity(logP)
|
2.9
|
Show
data source
|
|
DETAILS
DETAILS
DrugBank
DrugBank -
DB01130
|
Item |
Information |
Drug Groups
|
approved |
Description
|
Prednicarbate is a relatively new topical corticosteroid drug. It is similar in potency to hydrocortisone. It is used in the treatment of inflammatory skin diseases, such as atopic dermatitis. It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. The anti-inflammation action of corticosteroids is associated with the inhibition of the interleukin 1-alpha cytokine within keratinocytes. IL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness. |
Indication |
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |
Pharmacology |
Corticosteroids diffuse across cell membranes and complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, bind to DNA (chromatin), and stimulate transcription of messenger RNA (mRNA) and subsequent protein synthesis of various inhibitory enzymes responsible for the anti-inflammatory effects of topical corticosteroids. These anti-inflammatory effects include inhibition of early processes such as edema, fibrin deposition, capillary dilatation, movement of phagocytes into the area, and phagocytic activities. Later processes, such as capillary production, collagen deposition, and keloid formation also are inhibited by corticosteroids. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Primarily in skin |
Absorption |
Absorbed systemically across the stratum corneum. |
References |
• |
Gupta AK, Chow M: A review of prednicarbate (Dermatop). Skin Therapy Lett. 2004 Dec-2005 Jan;9(10):5-6, 9.
[Pubmed]
|
|
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent